Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786668 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
A Phase 2 study of Ankylosing Spondylitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT01786668 is a Phase 2 study of Ankylosing Spondylitis that has completed, run by Pfizer. The registered enrollment target is 208 participants, below the 38,183-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT01786668, a Phase 2 study of Ankylosing Spondylitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tofacitinib 2 mg
- DRUG Tofacitinib 5 mg
- DRUG Tofacitinib 10 mg
Study Locations (20)
Florida
- Arthritis & Rheumatology Associates - Clearwater
- Millennium Research - Ormond Beach
- Southwest Florida Clinical Research Center - Tampa
Nebraska
- Advanced Medical Imaging (MRI center) - Lincoln
- Arthritis Center of Nebraska (X-ray center) - Lincoln
- Physician Research Collaboration, LLC - Lincoln
North Carolina
- Charlotte Radiology/ Carolina Imaging Services - Ballantyne
- Joint and Muscle Research Institute - Charlotte
- Presbyterian Imaging - Charlotte
California
- Desert Medical Imaging - Indian Wells
- Desert Medical Advances - Palm Desert
Maryland
- Klein & Associates, M.D., P.A. - Hagerstown
- Progressive Radiology - Hagerstown
Ohio
- Paramount Medical Research & Consulting, LLC - Middleburg Heights
- Premier Physicians Centers - Westlake
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
- Clinical Research Center of Reading, LLC - Wyomissing
Indiana
- Covance Central Laboratory Services,Inc - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786668
The ClinicalTrials.gov registry entry for NCT01786668 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38,183-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ankylosing Spondylitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01786668 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Nebraska, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01786668 about?
NCT01786668 is a clinical study titled "Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis". This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
What is the current status of trial NCT01786668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2013-04. Estimated completion is 2015-03.
What conditions does trial NCT01786668 study?
This clinical trial studies the following conditions: Ankylosing Spondylitis.
What interventions are being tested in trial NCT01786668?
The interventions under investigation include: Placebo (DRUG), Tofacitinib 2 mg (DRUG), Tofacitinib 5 mg (DRUG), Tofacitinib 10 mg (DRUG).
Who is sponsoring clinical trial NCT01786668?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01786668 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ankylosing Spondylitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
RECRUITING
-
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.